NewAmsterdam Pharma

Lipid-lowering therapeutics

NAMS · Nasdaq · Netherlands

Share price · NAMS

$19.74-7.51 (-27.56%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.8M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NAMS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+8.0%
  2. 23 Oct 2026-8.7%
  3. 9 Sep 2026-11.1%

    Nothing announced by NAMS that day or the session before.

  4. 8 May 2026+11.1%
  5. 7 May 2026+12.5%
  6. 14 Apr 2026-5.0%

    Nothing announced by NAMS that day or the session before.

  7. 2 Mar 2026-7.4%
  8. 3 Dec 2025-7.3%

Share of unusual movement by asset

For each asset, the share of NAMS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Obicetrapib
events and moves
7shown from 8 days
Obicetrapib/ezetimibe (Evlarco) (Evlarco)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—29%
Other company news (earnings, financing, releases naming no asset)—20%
Sessions with no dated event—51%

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
CETPSmall molecule
Type 2 DiabetesAtherosclerotic Cardiovascular DiseaseAlzheimer's Disease
Early Alzheimer's Disease
Phase 3
CETP · NPC1L1Small molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (2)
ObicetrapibPhase 2Dyslipidemias
Est. primary completion 2026-11 · NCT06496243 · CT.gov ↗
What to watch
ObicetrapibPhase 3Atherosclerotic Cardiovascular Disease
Est. primary completion 2026-11 · NCT05202509 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
ObicetrapibPhase 3Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
Est. primary completion 2028-03 · NCT07219602 · CT.gov ↗
What to watch
September 2028 (1)
ObicetrapibPhase 2Preclinical Alzheimer's Disease
Est. primary completion 2028-09 · NCT07794670 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

21 September 2026ApprovalObicetrapibEuropean Commission approves Ubeslo (obicetrapib)
EU, EC · NewAmsterdam Pharma and Menarini Group · Source ↗
21 September 2026ApprovalObicetrapib/ezetimibe (Evlarco)European Commission approves Evlarco
EU, EC · NewAmsterdam Pharma and Menarini Group · Source ↗
18 August 2025Filing acceptedObicetrapibEMA validates obicetrapib MAA
EU, EMA · Source ↗
20 November 2024Topline resultObicetrapibPhase 3 TANDEM topline: obicetrapib/ezetimibe FDC met all co-primary endpoints

Financial reports

Quarterly & interim (12)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$19M$39M$423M+ $205M short-term inv.$17M-$40M operating cash flowreport ↗
View 11 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$3.7M$42M$424M+ $210M short-term inv.$64M-$39M operating cash flowreport ↗
2026-Q1$3.0M$38M$458M+ $179M short-term inv.$48M-$31M operating cash flowreport ↗
2025-Q3$0.3M$31M$538M+ $165M short-term inv.$72M-$33M operating cash flowreport ↗
2025-Q2$19M$28M$564M+ $175M short-term inv.$17M-$38M operating cash flowreport ↗
2025-Q1$3.0M$45M$748M+ $60M short-term inv.$40M-$36M operating cash flowreport ↗
2024-Q3$29M$36M$423M$17M-$13M operating cash flowreport ↗
2024-Q2$2.3M$38M—$39M-$54M operating cash flowreport ↗
2024-Q1$1.4M$42M—$94M-$55M operating cash flowreport ↗
2023-Q3$2.9M$43M—$47M-$47M operating cash flowreport ↗
2023-Q2$1.7M$34M—$38M-$29M operating cash flowreport ↗
2023-Q1$8.6M$40M—$42M-$32M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$23M$142M$490M+ $146M short-term inv.$51M-$148M operating cash flowreport ↗

NewAmsterdam Pharma reported full-year 2025 revenue of $22.5M, down 50.6% YoY, with R&D expenses of $141.83M, down 6.3% YoY. The company ended the year with $490M in cash and cash equivalents, or $728.9M including marketable securities, and reported a net loss of $203.82M.

Management guided to approval decisions from EMA, UK and Switzerland regulators for obicetrapib and the fixed-dose combination expected in the second half of 2026, topline data from the Phase 3 RUBENS trial by year-end 2026, and a planned new clinical trial in early Alzheimer’s disease patients in 2026. The blinded MACE event rate in the Phase 3 PREVAIL cardiovascular outcomes trial through the initial 12 months was in line with the BROADWAY trial, and cash runway is expected to fund operations through the PREVAIL readout and, if approved, support a subsequent U.S. commercial launch.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$46M$151M$772M+ $62M short-term inv.$60M-$159M operating cash flowreport ↗
2023-FY$14M$159M$340M$44M-$141M operating cash flowreport ↗
2022-FY$103M$87M—$5.7M$11M operating cash flowreport ↗
2021-FY—$29M—$10M-$30M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($227K), 43 sales ($63.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-30Kastelein Johannes Jacob Pieter · director, Chief Scientific OfficerOption exercise50,246——Form 4
2026-09-30Kastelein Johannes Jacob Pieter · director, Chief Scientific OfficerOpen-market sale50,246$25.03$1.3MForm 4
2026-09-30Kastelein Johannes Jacob Pieter · director, Chief Scientific OfficerOption exercise (derivative)50,246——Form 4
2026-09-14Davidson Michael H. · director, Chief Executive OfficerOpen-market purchase10,000$22.65$227KForm 4
2026-09-04Smither John W · directorOpen-market sale1,600$25.32$41KForm 4
2026-09-01Gunning Robert William · Vice President, ControllerAward / grant3,200——Form 4
2026-09-01Gunning Robert William · Vice President, ControllerAward / grant (derivative)14,000——Form 4
2026-08-24Kastelein Johannes Jacob Pieter · director, Chief Scientific OfficerOption exercise125,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 167 reporting institutions held 123.1M shares ($3.8B, 105.3% of shares outstanding).

#InstitutionSharesValue
1Frazier Life Sciences Management, L.P.16,943,774$542.4M
2Capital World Investors11,109,034$355.6M
3RA CAPITAL MANAGEMENT, L.P.9,550,191$305.7M
4FCPM III SERVICES B.V.9,198,900$294.5M
5FMR LLC8,765,811$280.6M
6Bain Capital Life Sciences Investors, LLC7,306,566$233.9M
7WELLINGTON MANAGEMENT GROUP LLP5,115,818$163.8M
8DEERFIELD MANAGEMENT COMPANY, L.P.4,264,789$136.5M
9VIKING GLOBAL INVESTORS LP4,203,567$134.6M
10Polar Capital Holdings Plc2,831,607$90.6M
11JENNISON ASSOCIATES LLC2,750,403$88.0M
12Medicxi Ventures Management (Jersey) Ltd2,674,182$85.6M
13JANUS HENDERSON GROUP PLC2,258,984$72.3M
14WESTFIELD CAPITAL MANAGEMENT CO LP2,202,913$70.5M
15MAVERICK CAPITAL LTD2,186,402$70.0M